Bio-Rad Laboratories, Inc. Class B

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BIO.B and other ETFs, options, and stocks.

About BIO.B

Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life Science and Clinical Diagnostics. 

CEO
Norman D. Schwartz
CEONorman D. Schwartz
Employees
7,450
Employees7,450
Headquarters
Hercules, California
HeadquartersHercules, California
Founded
1952
Founded1952
Employees
7,450
Employees7,450

BIO.B Key Statistics

Market cap
8.14B
Market cap8.14B
Price-Earnings ratio
49.45
Price-Earnings ratio49.45
Dividend yield
Dividend yield
Average volume
15.71
Average volume15.71
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$321.12
52 Week high$321.12
52 Week low
$244.54
52 Week low$244.54

Stock Snapshot

The current Bio-Rad Laboratories, Inc. Class B(BIO.B) stock price is $304.15, with a market capitalization of 8.14B. The stock trades at a price-to-earnings (P/E) ratio of 49.45.

During the trading day, Bio-Rad Laboratories, Inc. Class B(BIO.B) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading volume for Bio-Rad Laboratories, Inc. Class B(BIO.B) stock has reached 0, versus its average volume of 15.71.

Over the past 52 weeks, Bio-Rad Laboratories, Inc. Class B(BIO.B) stock has traded between a high of $321.12 and a low of $244.54.

Over the past 52 weeks, Bio-Rad Laboratories, Inc. Class B(BIO.B) stock has traded between a high of $321.12 and a low of $244.54.

BIO.B News

Nasdaq 2h
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026?

Key Points Bio-Rad Laboratories offers high profitability and a liquid balance sheet with a current ratio above 5x. Charles River Laboratories International m...

Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026?
Simply Wall St 4d
How Stronger Results and Institutional Selling At Bio-Rad Laboratories Has Changed Its Investment Story

Recently, Bio-Rad Laboratories reported year-over-year growth in both revenue and net profit while institutional investors, led by First Eagle Investment, signi...

How Stronger Results and Institutional Selling At Bio-Rad Laboratories Has Changed Its Investment Story

Analyst ratings

50%

of 6 ratings
Buy
33.3%
Hold
50%
Sell
16.7%

People also own

Based on the portfolios of people who own BIO.B. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.